At the news
? BEARISHIMPACT 7/10 424B5 filed May 19, 2026 at 17:25 ET
Annovis Bio filed a preliminary 424B5 for an underwritten offering of common stock and warrants, with no final pricing disclosed. The company has a going concern, cash of $14.2M (insufficient for 12 months), and an accumulated deficit of $181.3M. The offering will be highly dilutive to existing shareholders.
- Preliminary prospectus for offering of common stock and warrants (nine-tenths warrant per share, six-year term).
- Cash and cash equivalents of $14.2M as of March 31, 2026, insufficient to fund operations for the next 12 months.
- Accumulated deficit of $181.3M; going concern uncertainty noted.
- Phase 3 Alzheimer's trial enrollment 85% complete; cash expected to last only until Q4 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access